1055. HAEMOPHILUS INFLUENZAE TYPE B INVASIVE DISEASE IN A PEDIATRIC HOSPITAL OF ARGENTINA.
Session: Poster Abstract Session: Assorted Pediatric Vaccines
Friday, October 6, 2017
Room: Poster Hall CD
Background:

Since

The vaccination strategy is a three-dose primary series (at two,

Active surveillance is important to opportunely detect variations on these trends.

Methods:

Cross-sectional study, including all hospitalized patients with Hib infection since 2012 to May 2017 at Hospital de Niños “Ricardo Gutiérrez” in Buenos Aires, Argentina.

Results:

Twenty previously healthy children were admitted.

Male/female ratio 1.8:1. Median age: 12 (range 45 days-114) months; 85% younger than 2 years and 35% younger than 6 months. Nine patients (45%) had complete vaccination schedule, with three or more doses of DTP-Hib-HBV vaccine. Hospitalization Hib infections by year in Table 1

Year

Hib admissions (n)

Total hospital admissions (n)

Hospitalization rates

(per 100.000 admissions/year )

2012

1

9764

1,02

2013

2

9304

2,15(IC 95% 0,26-7,76)

2014

3

9066

3,31(IC95% 0,68- 13,81)

2015

6

9450

6,35 (IC 95% 2,33- 13,81)

2016

8

9780

8,18 (IC 95% 3,5 – 16,11)

Clinical presentation: meningitis (14/20), pneumonia (6/20) and arthritis (5/20), osteomyelitis (1/20). All patients with meningitis, 25% of pneumonias and 50% of arthritis had positive blood cultures.

Hib was isolated from blood in 17/20 cases, cerebrospinal fluid in 7/14, joint fluid in 3/5 and pleural fluid in 2/6.

Median WBC: 12,400/mm3 (1600 - 42,900) and median C-reactive protein level 111mg/L (7-358). Median days of hospitalization was 13 (8-40).

Nine patients required intensive care, four of them required mechanical ventilation. None patients died. Immunological studies ruled out immunodeficiency in 10 patients, although four continues under study.

Conclusion:

  • Burden of invasive Hib infections have increased over the last few years in our setting.
  • Most of patient had adequate immunization schedule for age
  • Surveillance studies should be continued to confirm these preliminary results as well as to evaluate possible causes
Eduardo Walter Yfran. E.W, MD1, Fausto M Ferolla, MD2, Carolina Carballo, MD1, Maria Marco Del Pont, MD3, Carolina Acosta IV, MD4, Marina Elisa Pasinovich, MD5, Carlos Mauricio Vergara Lobo, MD6, Claudia I Cazes, MD7, Maria Laura Praino, MD8, Christian Campoverde, MD9, María M Contrini, MD10 and Eduardo L Lopez, MD11, (1)Infectious Disease Department, Hospital de Niños "Ricardo Gutiérrez", Buenos Aires, Argentina, (2)Pediatric Infectious Disease, Hospital de Niños "Dr. Ricardo Gutiérrez", Buenos Aires, Argentina, (3)Hospital de Niños "Ricardo Gutiérrez, Infectious Diseases Department, Buenos Aires, Argentina, (4)hospital de niños ricardo gutierrez departamento de infectología, buenos aires, Argentina, (5)Hospital de Niños Dr. Ricardo Gutiérez, Ciudad Autónoma de Buenos Aires, Argentina, (6)Infectologia, Hospital de Niños "Ricardo Gutierrez", Universidad de Buenos Aires, Buenos aires, Argentina, (7)Hospital de Niños R. Gutiérrez, Buenos Aires, Argentina, (8)Infectious Diseases, Hospital Ricardo Gutiérrez, Buenos Aires, Argentina, (9)Hospital de Niños Ricardo Gutierez, Buenos Aires, Argentina, (10)Infectious Diseases, Hospital de Niños "R. Gutiérrez", Buenos Aires, Argentina, (11)Department of Medicine, Hospital de Niños "Ricardo Gutiérrez", Buenos Aires, Argentina

Disclosures:

E. W. Yfran. E.W, None

F. M. Ferolla, None

C. Carballo, None

M. Marco Del Pont, None

C. Acosta IV, None

M. E. Pasinovich, None

C. M. Vergara Lobo, None

C. I. Cazes, None

M. L. Praino, None

C. Campoverde, None

M. M. Contrini, None

E. L. Lopez, None

Previous Abstract | Next Abstract >>

Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 4th with the exception of research findings presented at the IDWeek press conferences.